Cancer therapy inhibits metastasis, spread of cancer
Cancer therapy inhibits metastasis, spread of cancer
Nucleic acid cancer therapy inhibtis metastasis, scar fromation and inflammation: This technology utilizes a cost-effective and cutting-edge nucleic acid therapeutic strategy (RNAi) to inhibit EB1 protein expression. EB1 inhibition prevents cell migration, a key step in metastasis and the spread of cancer throughout the body.
New York, NY, United States
Overview Comments Tagged publications

Background

Cancer therapy to prevent metastasis: As the incidence of cancer continues to rise, additional therapeutic technologies are needed more than ever. Current adjuvant therapies inject hormones, antibodies, or other peptides into the patient; however, these therapeutics are expensive to manufacture and do not always prevent metastasis (the spread of the cancer to other parts of the body.) Novel and more cost-effective classes of cancer therapeutic strategies are critical for improved prevention of metastasis that results in the spread of cancer. 

Nucleic acid cancer therapy inhibtis metastasis, scar fromation and inflammation: This technology utilizes a cost-effective and cutting-edge nucleic acid therapeutic strategy (RNAi) to inhibit EB1 protein expression. EB1 inhibition prevents cell migration, a key step in metastasis and the spread of cancer throughout the body. This technology can also be used to inhibit scar formation and inflammation following physical trauma in a patient. 

Applications: • Inhibition of cell metastasis and the spread of cancer throughout the body • Inhibition of scar formation in a subject following the affliction of physical trauma • Reduction of inflammation in a subject

Advantages: • Novel nucleic acid segment that inhibits EB1 and cell migration • Can be used to treat a number of conditions including cell metastasis, scar formation, and inflammation • Nucleic acid therapeutic production more cost-effective than traditional peptide therapeutics

Publications: Nature Cell Biology, September 2004, 6(9):820-30.

Lead Inventor: Gregg G. Gundersen, Ph.D.

No comments.
No tagged publications.

Similar innovations

Back
or
Back
Back
or
Back
  • Gene therapy for inflammatory and autoimmune diseases
  • This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Parkinson's and Huntington's Treatment
  • This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Binding Partner to Tumor Suppressor
  • HAUSP (herpesvirus-associated ubiquitin-specific protease) as a novel p53-interacting deubiquitinase. HAUSP strongly stabilizes p53 by deubiquitinating p53, even in the presence of excess Mdm2. In addition, HAUSP binds directly to Mdm2 in such a way as to form a three-protein complex with p53 and, via this indirect interaction, p53 is also stabilized. The technology provides methods for screening HAUSP-p53 and HAUSP-Mdm2 interactions.
  • Read more
  • TherapeuticsMethods
  • New York, NY, United States
  • Stanford University
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 159

Send Us a Message